Goldman Sachs Global Healthcare Conference June 10, 2025 Jay Duker, M.D. President and CEO ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the futur ...

Investor Presentation February 2025 Most robust dataset in wet AMD and DME among all sustained delivery programs in development Two ongoing global Phase 3 non-inferiority pivotal trials in wet AMD Only sustained release TKI with active program in DME bolstered by highly positive Phase 2 clinical data ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, int ...

EyePoint Pharmaceuticals (EYPT) FY Conference June 10, 2025 02:40 PM ET Speaker0 Good afternoon. Thanks for listening. My name is Jay Duker. I'm the president and CEO of EyePoint. I'd like to thank Goldman Sachs for inviting us to present today. And we are a publicly traded company, and I will be giving some forward looking statements. If you'd like our full legal disclaimers, I invite you to go to our website. EyePoint is the leader in sustained release drug delivery for retinal diseases. Our lead asset is ...

Group 1: Market Overview - High volatility in markets throughout 2025 has created opportunities for momentum investors to capture gains when target stocks rise [1] - Timing momentum plays can be challenging, but early identification of targets in a sustained rally can provide an advantage [1] Group 2: EyePoint Pharmaceuticals (EYPT) - EyePoint Pharmaceuticals, a clinical-stage biopharma firm, has seen its stock price forecasted to reach $25.38, indicating a potential upside of 188.39% from the current price of $8.80 [2] - The company reported first-quarter revenue of nearly $25 million, significantly exceeding analyst expectations of just under $9 million [3] - EyePoint's lead drug candidate, DURAVYU, is in a critical Phase 3 clinical trial, with top-line data expected in 2026 [4] - The company ended the first quarter with over $318 million in cash and investments, sufficient to sustain operations through 2027 [4] - EYPT shares have increased by more than 19% in the last month, with analysts suggesting that growth is just beginning [5] Group 3: Nova Ltd. (NVMI) - Nova Ltd., which designs process control systems for semiconductor manufacturing, has a stock price forecast of $277, representing a 26.02% upside from the current price of $219.81 [6] - The company reported quarterly revenue growth of over 50% year-over-year, with earnings per share of $2.18 beating analyst estimates by 10 cents [7] - Analysts project Nova's earnings growth could exceed 7% in the future, supported by a year-over-year cash flow growth of about 32% [8] - NVMI shares have risen by more than 10% in the last month, with a consensus price target suggesting over 27% upside potential [9] Group 4: Ouster Inc. (OUST) - Ouster Inc. specializes in LiDAR technology for 3D mapping and imaging, with a stock price forecast of $14.10, indicating a 2.45% upside from the current price of $13.76 [10] - The company reported first-quarter revenue of $33 million, a 26% year-over-year increase, and a GAAP gross margin improvement to 41% from 29% [11] - Ouster projects second-quarter revenue between $32 million and $35 million, indicating significant upside potential [11] - The company's stock has rallied over 71% in the last year, with analysts optimistic about further growth due to increasing demand for robotics and automation services [12]

Summary of EyePoint Pharmaceuticals (EYPT) 2025 Conference Call Company Overview - **Company**: EyePoint Pharmaceuticals (EYPT) - **Event**: 2025 Conference Call on May 27, 2025 - **Key Speakers**: George Elson (CFO), Romero Ribeiro (Chief Medical Officer) Key Points Industry and Product Development - EyePoint Pharmaceuticals is focused on the ophthalmology market, specifically targeting wet age-related macular degeneration (AMD) and diabetic macular edema (DME) with its product DuraVu, a potent and selective TKI (tyrosine kinase inhibitor) [3][4] - The company has completed enrollment in the first of two phase three pivotal trials for DuraVu, with over 400 patients enrolled in seven months [3] - The second trial, LUCHIA, is 60% enrolled and expected to complete enrollment in Q3 2025 [3] Clinical Trial Progress - Positive 24-week data for DuraVu in DME was reported earlier in the year, with an end-of-phase two meeting with the FDA scheduled for early July [5] - The company has a new 41,000 square foot facility in Northbridge, Massachusetts, capable of producing millions of doses for global launch [5][6] - The company has cash reserves extending into 2027, ensuring financial stability through upcoming data readouts [6] Market Positioning and Strategy - DuraVu is positioned as a maintenance therapy for wet AMD, aiming to reduce the treatment burden associated with frequent anti-VEGF injections [8][11] - The company emphasizes that DuraVu is not just another anti-VEGF but offers a new mechanism of action, potentially allowing patients to go longer periods without additional treatments [9][12] - The phase two data indicated that 66% of patients did not require anti-VEGF for six months, and 50% did not require it for up to one year [12][28] Safety and Efficacy - The safety profile of DuraVu has been excellent, with no serious adverse events reported related to the treatment [28] - The phase two study showed non-inferiority in visual outcomes compared to aflibercept, with an 80% reduction in treatment burden [28] Regulatory and Commercial Readiness - The company is preparing for NDA filing and has designed its trials to align with FDA requirements, including the use of sham controls [52][55] - A pre-commercial team is actively engaging with payers and key opinion leaders to ensure readiness for market entry [63] Future Milestones - Upcoming data readouts for the Lugano trial are expected in mid-2026, with the Lucia trial following shortly thereafter [62] - The company is focused on executing its commercial strategy and ensuring manufacturing capabilities are in place for a successful launch [63] Additional Insights - The retinal community is receptive to innovations that reduce treatment burdens, indicating a strong market need for DuraVu [22] - The design of the phase three trials incorporates lessons learned from phase two, ensuring robust patient selection and treatment criteria [32][41] - The company aims to provide flexibility in dosing, with a six-month label that allows for redosing if necessary [60] This summary encapsulates the key points discussed during the EyePoint Pharmaceuticals conference call, highlighting the company's strategic direction, clinical progress, and market positioning within the ophthalmology sector.

Core Insights - EyePoint Pharmaceuticals has enrolled over 400 patients in the Phase 3 LUGANO trial for DURAVYU, surpassing its enrollment target and indicating strong interest from both physicians and patients [1][3] - The LUGANO trial is part of a pivotal Phase 3 program designed in alignment with the FDA, with topline data expected in mid-2026 [2][3] - DURAVYU aims to provide a sustained-release treatment option for wet age-related macular degeneration (wet AMD), addressing significant patient needs and market potential [3][5] Company Overview - EyePoint Pharmaceuticals is focused on developing innovative therapeutics for serious retinal diseases, leveraging its proprietary Durasert E™ technology for sustained intraocular drug delivery [9][10] - The lead product candidate, DURAVYU, is a sustained delivery treatment for VEGF-mediated retinal diseases, utilizing vorolanib, a selective tyrosine kinase inhibitor [6][9] - The company has established a robust safety and efficacy profile for DURAVYU, with positive results from previous clinical trials demonstrating significant treatment burden reduction [7][9] Clinical Trials - The LUGANO and LUCIA trials are randomized, double-masked, aflibercept-controlled, non-inferiority Phase 3 trials assessing DURAVYU's efficacy and safety in wet AMD patients [3][4] - The LUGANO trial has completed enrollment, while the LUCIA trial is expected to complete enrollment by the third quarter of 2025 [1][3] - Both trials are designed to evaluate the average change in best corrected visual acuity (BCVA) and other secondary endpoints over a two-year period [3][4] Market Context - Wet AMD is a leading cause of vision loss in individuals over 50, requiring continuous treatment and posing a significant burden on patients and healthcare systems [5] - Current treatments require frequent dosing, which can lead to patient noncompliance and further vision loss, highlighting the need for innovative solutions like DURAVYU [5][6] - The potential for DURAVYU to transform the treatment paradigm for wet AMD is underscored by its unique delivery mechanism and favorable safety profile [3][6]

Summary of EyePoint Pharmaceuticals (EYPT) 2025 Conference Call Company Overview - EyePoint Pharmaceuticals is focused on drug delivery to the back of the eye, specifically through its program DURAVU, which is currently in two global Phase III trials named Lugano and LUCIA, with enrollment progress reported as over 90% for Lugano and over 50% for LUCIA [2][3][4]. Clinical Trials and Progress - The company is well-funded to reach data points in 2026, with complete enrollment expected in the second half of 2025 for both trials [4]. - The FDA has been responsive, with no disruptions reported in communications, and an end of Phase II meeting scheduled for early July [6][7]. Market Landscape and Product Positioning - The wet AMD market is valued at $15 billion, primarily dominated by anti-VEGF therapies. EyePoint's DERVIEW is positioned as a new mechanism of action (MOA) that combines a receptor binder and tyrosine kinase inhibitor, potentially offering benefits beyond existing treatments [12][13]. - DERVIEW is designed as a maintenance therapy, allowing patients to remain stable on anti-VEGF treatments while also receiving DERVIEW [15][48]. Regulatory Strategy - EyePoint has engaged with regulatory authorities globally, with EMA approval for clinical trials in Europe recently obtained [21][22]. - The company plans to launch DERVIEW solo in the U.S. and seek a partner for international markets [22][44]. Enrollment and Market Dynamics - Enrollment for the trials has exceeded expectations, with a noted acceleration in patient participation despite challenges in the broader market [28][29]. - The company anticipates that the current funding issues for co-pay assistance programs may inadvertently benefit enrollment in clinical studies [28]. Safety and Efficacy Considerations - The company is focused on maintaining low supplemental injection rates in its trials, with strict criteria established to minimize these rates [32][33]. - Preclinical data supports the safety and efficacy of DERVIEW, with confidence in the new dosing regimen for the pivotal studies [34][36]. Future Opportunities - EyePoint is also exploring DERVIEW for diabetic macular edema (DME), with promising early data indicating significant improvements in vision and fluid reduction [38][39]. - The company sees potential for DERVIEW in other indications, with plans to evaluate these opportunities post-2026 [41]. Commercialization Strategy - A potential premium pricing strategy for DERVIEW is being considered, reflecting its unique position in the market compared to anti-VEGF therapies [42]. - The U.S. market for retina specialists is relatively small, with about 2,400 doctors, which could be effectively approached with a modest sales team of around 70 representatives [44]. Conclusion - EyePoint Pharmaceuticals is making significant strides in the development of DERVIEW, with a clear strategy for clinical trials, regulatory engagement, and market positioning. The company is optimistic about its future prospects in both wet AMD and DME markets, while also preparing for a potential solo launch in the U.S.

Financial Performance - Total revenues for the three months ended March 31, 2025, increased by 109% to $24.45 million compared to $11.68 million in the same period of 2024[92]. - Royalty income surged by 2641% to $12.69 million for the three months ended March 31, 2025, compared to $463,000 in the prior year[92]. - The net loss for the three months ended March 31, 2025, was $45.20 million, a 54% increase from the net loss of $29.28 million in the prior year[92]. - License and collaboration agreement revenue increased by 5% to $11.05 million for the three months ended March 31, 2025, due to higher recognition of deferred revenue related to YUTIQ®[94]. - Total cash outflows from operating activities for the three months ended March 31, 2025, were $53.1 million, primarily due to a net loss of $45.2 million[107]. - The company had a total accumulated deficit of $918.2 million as of March 31, 2025, reflecting a history of operating losses[101]. - Interest income from investments decreased by $0.4 million, or 10%, to $3.6 million for the three months ended March 31, 2025, due to lower interest rates[100]. - General and administrative expenses decreased by $0.2 million, or 2%, to $13.9 million for the three months ended March 31, 2025[99]. - Net cash provided by investing activities was $39.5 million for the three months ended March 31, 2025, compared to $20.8 million in the same period of 2024[107]. - The company expects to continue incurring substantial operating losses as it develops product candidates and seeks marketing approval[103]. - The company did not sell any shares of common stock under its ATM offering facility during the three months ended March 31, 2025[102]. Research and Development - Research and development expenses rose by 94% to $58.57 million for the three months ended March 31, 2025, compared to $30.14 million in the same period of 2024[92]. - Research and development expenses rose by $28.4 million, or 94%, to $58.6 million for the three months ended March 31, 2025, driven mainly by increased clinical trial costs for DURAVYU™[97]. - DURAVYU™ is currently in global Phase 3 clinical trials (LUGANO and LUCIA) for wet age-related macular degeneration, with enrollment expected to complete in the second half of 2025[85]. - The Phase 2 VERONA clinical trial for DURAVYU™ in diabetic macular edema met both primary and secondary endpoints, showing significant improvements in vision[91]. - The company expects to report top-line data from the DURAVYU™ trials in the second half of 2026[85]. - The company is focused on finalizing the pivotal program for DURAVYU™ in diabetic macular edema with the US FDA in the second quarter of 2025[85]. Cash and Investments - The company had cash, cash equivalents, and investments totaling $318.2 million as of March 31, 2025, expected to fund operations into 2027[79]. - Cash, cash equivalents, and investments in marketable securities totaled $318.2 million as of March 31, 2025, expected to fund operations into 2027[103].

Core Insights - EyePoint Pharmaceuticals reported a revenue of $24.45 million for the quarter ended March 2025, marking a significant increase of 109.4% year-over-year [1] - The company's earnings per share (EPS) was -$0.65, slightly worse than the -$0.55 EPS from the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate by 345.17%, which was set at $5.49 million [1] - The consensus EPS estimate was also -$0.65, indicating no EPS surprise [1] Revenue Breakdown - Royalty income reached $12.69 million, significantly surpassing the three-analyst average estimate of $0.33 million [4] - Product sales, net, amounted to $0.72 million, slightly below the two-analyst average estimate of $0.85 million [4] - Revenue from license and collaboration agreements was $11.05 million, exceeding the average estimate of $6.90 million based on two analysts [4] Stock Performance - EyePoint Pharmaceuticals' shares have returned +51.3% over the past month, outperforming the Zacks S&P 500 composite, which saw a +10.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]